Skip to main content
Prabha Viswanathan, MD, Pediatric Infectious Disease, Washington, DC

Prabha Viswanathan MD


Physician

Join to View Full Profile
  • 111 Michigan Ave NWSte 100Washington, DC 20010

  • Phone+1 202-476-6151

  • Fax+1 202-476-3850

Dr. Viswanathan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Prabha Viswanathan is a specialist in Pediatric Infectious Disease based in Washington, DC. She completed her fellowship in Pediatric Infectious Diseases at Children's National Hospital/George Washington University from 2010 to 2013, following her medical degree from the University of Kansas School of Medicine in 2003, and a Pediatrics residency at the Children's Hospital of Philadelphia, which she completed in 2006. Dr. Viswanathan has published various papers, with topics including antiretroviral regimens and pharmacokinetics in pediatric patients, contributing significantly to relevant medical literature.

Education & Training

  • Children's National Hospital/George Washington University
    Children's National Hospital/George Washington UniversityFellowship, Pediatric Infectious Diseases, 2010 - 2013
  • Children's Hospital of Philadelphia
    Children's Hospital of PhiladelphiaResidency, Pediatrics, 2003 - 2006
  • University of Kansas School of Medicine
    University of Kansas School of MedicineClass of 2003

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2010 - 2027
  • Pediatrics
    American Board of Pediatrics Pediatrics
  • Pediatric Infectious Diseases
    American Board of Pediatrics Pediatric Infectious Diseases

Publications & Presentations

PubMed

Journal Articles

  • Effects of Sorbitol on the Pharmacokinetics of Lamivudine Solution and the FDA's Decision to Increase the Dose of Lamivudine Solution for Pediatric Patients  
    Prabha Viswanathan, MD, Clinical Pharmacology & Therapeutics

Press Mentions

  • Schools Should Normalize Pauses for Coronavirus Safety
    Schools Should Normalize Pauses for Coronavirus SafetyJanuary 25th, 2022

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: